NO986103L - Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer - Google Patents

Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer

Info

Publication number
NO986103L
NO986103L NO986103A NO986103A NO986103L NO 986103 L NO986103 L NO 986103L NO 986103 A NO986103 A NO 986103A NO 986103 A NO986103 A NO 986103A NO 986103 L NO986103 L NO 986103L
Authority
NO
Norway
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
type
Prior art date
Application number
NO986103A
Other languages
English (en)
Norwegian (no)
Other versions
NO986103D0 (no
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO986103L publication Critical patent/NO986103L/no
Publication of NO986103D0 publication Critical patent/NO986103D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO986103A 1996-06-25 1998-12-23 Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE NO986103D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25
PCT/IB1997/000630 WO1997049702A1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Publications (2)

Publication Number Publication Date
NO986103L true NO986103L (no) 1998-12-23
NO986103D0 NO986103D0 (no) 1998-12-23

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO986103A NO986103D0 (no) 1996-06-25 1998-12-23 Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE

Country Status (43)

Country Link
US (1) US6040329A (de)
EP (1) EP0912558B1 (de)
JP (1) JP3152940B2 (de)
KR (1) KR20000022516A (de)
CN (1) CN1080260C (de)
AP (1) AP1025A (de)
AR (1) AR007456A1 (de)
AT (1) ATE244713T1 (de)
AU (1) AU716376B2 (de)
BG (1) BG64052B1 (de)
BR (1) BR9712782A (de)
CA (1) CA2258285C (de)
CO (1) CO4900056A1 (de)
CZ (1) CZ423398A3 (de)
DE (1) DE69723447T2 (de)
DK (1) DK0912558T3 (de)
DZ (1) DZ2254A1 (de)
EA (1) EA002274B1 (de)
ES (1) ES2201299T3 (de)
GT (1) GT199700075A (de)
HK (1) HK1018700A1 (de)
HN (1) HN1997000079A (de)
HR (1) HRP970350B1 (de)
HU (1) HUP9903009A3 (de)
ID (1) ID18579A (de)
IL (1) IL127036A (de)
IS (1) IS4910A (de)
MA (1) MA24225A1 (de)
MY (1) MY116915A (de)
NO (1) NO986103D0 (de)
NZ (1) NZ332752A (de)
OA (1) OA10934A (de)
PA (1) PA8432301A1 (de)
PL (1) PL330974A1 (de)
PT (1) PT912558E (de)
SI (1) SI0912558T1 (de)
SK (1) SK176598A3 (de)
TN (1) TNSN97108A1 (de)
TR (1) TR199802685T2 (de)
TW (1) TW434237B (de)
WO (1) WO1997049702A1 (de)
YU (1) YU60198A (de)
ZA (1) ZA975581B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
EA002113B1 (ru) * 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
HUP0100330A3 (en) * 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use
AU754734B2 (en) * 1997-11-04 2002-11-21 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EP1244649B1 (de) * 1999-12-23 2005-03-02 Icos Corporation Cyclische amp spezifische phosphodiesterase inhibitoren
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
WO2002083648A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compound
PT1463493E (pt) 2001-12-14 2008-01-04 Serono Lab Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
CA2492911A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
AU2003256616B2 (en) 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
DE60334243D1 (de) 2002-11-19 2010-10-28 Memory Pharmaceutical Corp Pyridin-n-oxidverbindungen alsphosphodiesterase-4-inhibitoren
CN1809559B (zh) * 2003-04-18 2010-06-02 记忆药物公司 作为磷酸二酯酶4抑制剂的吡唑衍生物
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
US7432266B2 (en) 2004-10-15 2008-10-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
EP1891060A2 (de) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited 3-indazolyl-isoxazoline derivate als typ-iv phosphodiesterase inhibitoren
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP1928866A1 (de) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituierte indazole als inhibitoren von phosphodiesterase typ-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2008224541B2 (en) 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101774035B1 (ko) * 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP3137454A1 (de) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (de) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
EP0787132A1 (de) * 1994-10-20 1997-08-06 Pfizer Inc. Bizyklische tetrahydropyrazolopyridine und ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
ID18579A (id) 1998-04-23
NZ332752A (en) 2001-04-27
DE69723447T2 (de) 2003-12-24
US6040329A (en) 2000-03-21
CN1080260C (zh) 2002-03-06
TW434237B (en) 2001-05-16
HRP970350A2 (en) 1998-06-30
HK1018700A1 (en) 1999-12-30
EA199801047A1 (ru) 1999-06-24
BR9712782A (pt) 1999-12-07
EP0912558B1 (de) 2003-07-09
CA2258285C (en) 2002-11-26
ZA975581B (en) 1998-12-24
HUP9903009A3 (en) 2002-01-28
BG103056A (en) 1999-10-29
TNSN97108A1 (fr) 2005-03-15
SI0912558T1 (en) 2003-10-31
PL330974A1 (en) 1999-06-21
ES2201299T3 (es) 2004-03-16
EA002274B1 (ru) 2002-02-28
AU716376B2 (en) 2000-02-24
TR199802685T2 (xx) 1999-03-22
ATE244713T1 (de) 2003-07-15
PA8432301A1 (es) 1999-12-27
HUP9903009A2 (hu) 2000-05-28
BG64052B1 (bg) 2003-11-28
AU2785797A (en) 1998-01-14
IL127036A (en) 2001-06-14
JP3152940B2 (ja) 2001-04-03
CO4900056A1 (es) 2000-03-27
HN1997000079A (es) 1997-12-26
EP0912558A1 (de) 1999-05-06
MY116915A (en) 2004-04-30
DE69723447D1 (de) 2003-08-14
DZ2254A1 (fr) 2002-12-18
OA10934A (en) 2002-02-18
CZ423398A3 (cs) 1999-12-15
KR20000022516A (ko) 2000-04-25
SK176598A3 (en) 2000-06-12
JPH11514668A (ja) 1999-12-14
DK0912558T3 (da) 2003-08-18
WO1997049702A1 (en) 1997-12-31
HRP970350B1 (en) 2003-04-30
AR007456A1 (es) 1999-10-27
AP1025A (en) 2001-11-19
IL127036A0 (en) 1999-09-22
CN1223651A (zh) 1999-07-21
AP9701020A0 (en) 1997-07-31
YU60198A (sh) 1999-09-27
MA24225A1 (fr) 1997-12-31
GT199700075A (es) 1998-12-04
CA2258285A1 (en) 1997-12-31
IS4910A (is) 1998-11-27
NO986103D0 (no) 1998-12-23
PT912558E (pt) 2003-11-28

Similar Documents

Publication Publication Date Title
NO986103L (no) Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer
NO991048D0 (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
NO985095D0 (no) Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodiesterase (PDE) type IV og produksjon av tumornekrosefaktor (TNF)
DK1475377T3 (da) Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
DK1000039T3 (da) Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
NO20001102L (no) 2,3-diaryl-pyrazolo[1,5-B]pyridazinderivater, deres fremstilling og anvendelse som cyklo-oksygenase 2 (COX-2) inhibitorer
NO20030958D0 (no) Pyrazolderivater og deres anvendelse som proteinkinase inhibitorer
DK1480962T3 (da) 5-Phenylthiazol-derivater og deres anvendelse som P1-3-kinaseinhibitorer
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
IS6083A (is) Notkun á CYP2D6 lötum í samsetningarmeðferðum
AU2002226911A1 (en) Indol derivative and their use as inhibitors of p38 kinase
NO923089D0 (no) Tetrahydroindazol, tetrahydrocyklopentapyrazol og heksahydrocykloheptapyrazol forbindelser og deres anvendelse som hmg-coa reduktase-hemmere
PT934280E (pt) Derivados 2-cianoiminoimidazolo inibidores da pde iv
NO985577D0 (no) Alkyloksyaminosubstituerte fluorenoner og deres anvendelse som proteinkinase C-inhibitorer
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
NO934227D0 (no) Pyrrolderivater, fremgangsm}te for deres fremstilling og terapeutiske anvendelse
NO20003199D0 (no) Benzo(C)kinolizinderivater og deres anvendelse som 5- <alfa>reduktaseinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application